Join the team at the American Society for Cell & Gene Therapy’s Annual meeting!
Mogrify is transforming the lives of patients through the development of a novel class of <em>in vivo </em>reprogramming therapies, initially addressing indications in ophthalmology, otology and metabolic and other areas of degenerative disease. Using its proprietary suite of platform to systematically identify the key transcriptomic and epigenetic switches required to drive direct cellular reprogramming.
Connect with our team virtually at the ASCGT Annual Meeting 2023.